Online CME/Enduring Materials

Emerging Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: Highlights from ASH 2018 - E117620

1.00 AMA PRA Category 1 Credits ^TM from March 28, 2019 thru March 28, 2020

This enduring panel discussion will review the efficacy and safety of emerging treatment options for patients with RRMM and discuss the clinical practice implications of these therapies in the context of currently approved therapies and treatment algorithms. This activity will also address practical strategies to individualize RRMM treatment paradigms, while considering both approved and investigational strategies, and accounting for patient-specific factors.

Optimizing the Use of Targeted Therapies into CLL Treatment Paradigms: Applying the Latest Evidence into Practice - E117673

1.00 AMA PRA Category 1 Credits ^TM from March 28, 2019 thru March 28, 2020

This interactive activity features 2 leading experts in CLL who discuss and debate the latest advances regarding novel and emerging targeted therapies for patients with CLL, as well as discuss the evolving role of prognostic molecular biomarkers in targeted therapy initiation and treatment selection, highlighting key data presented at the 2018 Annual Meeting and Exposition of the American Society of Hematology (ASH).

Evolving Considerations in Immuno-Oncology: Bridging the Gaps Between Research and Clinical Care Program - E117651

1.00 AMA PRA Category 1 Credits ^TM from April 22, 2019 thru April 22, 2020

The goal of this international, on-demand web portal is to inform oncology HCPs on the clinical rationale of checkpoint inhibitor (CPI) use across various cancers; the latest efficacy and safety data that may inform patient selection; practical strategies for effective CPI use and the management of treatment-related adverse events; and potential region-specific variations in CPI clinical utility.

Practicing in an Era of Chemotherapy-Free Regimens for Relapsed/Refractory Chronic Lymphocytic Leukemia - E117717-2

1.00 AMA PRA Category 1 Credits ^TM from June 24, 2019 thru June 24, 2020

This educational curriculum will improve the ability of learners to: assess key prognostic, predictive, and clinical factors that drive the factors for considering 2^nd line therapy for patients with CLL;  utilize the most recent evidence-based guidelines for the care of individuals with  R/R CLL; describe key clinical trial results and subset analyses demonstrating the efficacy and safety of targeted regimens in the R/R CLL and understand the implications of these data for practice; understand the clinical trial endpoints of overall survival, response rate, and clearance of minimal residual disease of venetoclax-rituxumab combination  therapy compared with bendamustine-rituxumab; and employ effective communication strategies using core SDM principles with patients with CLL and their caregivers. It is anticipated that these practice improvements will lead, by extension, to improved patient outcomes.

Preview Mode: Emergence of Chemotherapy-Free Regimens for Previously Untreated and Relapsed/Refractory CLL: Highlights from ASCO 2019 - E11717-1

.50 AMA PRA Category 1 Credits ^TM from June 28, 2019 thru June 28, 2020

This educational curriculum will improve the ability of learners to: assess key prognostic, predictive, and clinical factors that drive the factors for considering 2^nd line therapy for patients with CLL;  utilize the most recent evidence-based guidelines for the care of individuals with  R/R CLL; describe key clinical trial results and subset analyses demonstrating the efficacy and safety of targeted regimens in the R/R CLL and understand the implications of these data for practice; understand the clinical trial endpoints of overall survival, response rate, and clearance of minimal residual disease of venetoclax-rituxumab combination  therapy compared with bendamustine-rituxumab; and employ effective communication strategies using core SDM principles with patients with CLL and their caregivers. It is anticipated that these practice improvements will lead, by extension, to improved patient outcomes.

Clinical Updates in Chronic Myeloid Leukemia (New Understanding in Disease Diagnosis - E117540 

.50 AMA PRA Category 1 Credits ^TM from April 1, 2019 thru April 1, 2020

MPT is the fastest online destination for clinicians seeking breaking medical news and education. News-Driven engagement means access to over 1.1 million readers on the site each month and over 730,000 validated physician members.

Exploring the Evolving Role of PARP Inhibition and Immunotherapy in Gynecological Cancers - T1003-E2

1.50 AMA PRA Category 1 Credits ^TM from September 3, 2019 thru September 3, 2020.

This live and on-demand educational initiative will feature animated video segments and leverage patient-focused content to facilitate learner interaction, and merge clinical decision-making with evidence-based concepts to provide memorable, relevant, and retainable learning encounters.
 

Targeting B-cell Maturation Antigen in Relapsed/Refractory Multiple Myeloma: New Findings in Clinical Context – T1006-E

2.00 AMA PRA Category 1 Credits TM from December 4, 2019 thru December 4, 2020

The curriculum is designed for hematologist/oncologists, nurse practitioners/physician assistants, pharmacists, and other health care providers and its collectively titled Targeting B-cell Maturation Antigen in Relapsed/Refractory Multiple Myeloma: New Findings in Clinical Context. The overarching goal of the education is to improve awareness, knowledge, and eventual competence in the use of novel therapies that target BCMA in the treatment of relapsed/refractory multiple myeloma.
 

Optimizing Shared Decision Making in Lung Cancer (Today’s Clinical Reality) E117619-1

.50 AMA PRA Category 1 Credits TM from January 2, 2020 thru January 2, 2021

This activity will assess shared decision making between physician and patients. Patient and physician interviews/questionnaires will be utilized to measure the concordance between oncologist communication and treatment intentions and lunch cancer patient comprehension and treatment intentions based on National Quality Partners PlaybookTM guidance and recommendations.
 

Optimizing Shared Decision Making in Lung Cancer (Strategies for Enhancing your Practice) E117619-2

.50 AMA PRA Category 1 Credits TM .50 AMA PRA Category 1 CreditsTM in the area of medical ethics and/or professional responsibility. from January 2, 2020 thru January 2, 2021

This activity will assess shared decision making between physician and patients. Patient and physician interviews/questionnaires will be utilized to measure the concordance between oncologist communication and treatment intentions and lunch cancer patient comprehension and treatment intentions based on National Quality Partners PlaybookTM guidance and recommendations.
 

Optimizing Shared Decision Making in Lung Cancer – E117619 

No CME Credits

Provider Tobacco and Nicotine Counseling for Adults and Adolescents - MEMV 1160

2.25 AMA PRA Category 1 Credits ^TM from June 12, 2017 thru June 12, 2020

This program is intended to educate physicians about the need to provide tobacco/nicotine counseling. It will cover current and future pharmacological options for tobacco/nicotine cessation, as well as behavioral treatments for nicotine dependence. The program will also illustrate practical skills for counseling adolescent patients about tobacco /nicotine products and providing age-appropriate prevention/cessation resources.